Christoph Höeller
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Cutaneous Melanoma Detection and Management, Melanoma and MAPK Pathways, Immunotherapy and Immune Responses
Most-Cited Works
- → Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial(2015)2,648 cited
- → Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial(2017)504 cited
- → Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial(2017)487 cited
- → Chemosensitisation of malignant melanoma by BCL2 antisense therapy(2000)481 cited
- → Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial(2021)373 cited
- → European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 2. Treatment(2020)310 cited
- → A Kinase-Independent Function of CDK6 Links the Cell Cycle to Tumor Angiogenesis(2013)302 cited
- → European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2022(2022)279 cited
- → Randomized, Double-Blind, Placebo-Controlled, Global Phase III Trial of Talimogene Laherparepvec Combined With Pembrolizumab for Advanced Melanoma(2022)249 cited
- → European interdisciplinary guideline on invasive squamous cell carcinoma of the skin: Part 1. epidemiology, diagnostics and prevention(2020)230 cited